Academic Program

Program

Wednesday, October 16, 2024

16:00 - 18:00 Early Registration

18:00 - 20:00 Welcome Reception

Conference Facilities at the Prague Marriott

Thursday, October 17, 2024

[7:45-8:00] Welcome to IWWM-12

Christian Buske, Jeffrey Matous, and Steven Treon [Workshop Organizers]

 

 

 

[8:00-9:00] Session I 

WM Predisposition

Romanos Sklavenitis-Pistofidis, Merav Leiba [Chairs]

 

Findings from the iSTOP Study

Sigurdur Kristinsson, Landspitali-The National University Hospital of Iceland, Iceland

 

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in WM Compared to IgM-MGUS

Stephen Ansell, Mayo Clinic, USA

 

Multi-Omics for Deciphering Mechanisms of Progression in Pre-Malignant IgM Gammopathies

Simone Ferrero, Università di Torino/Ematologia Universitaria, Italy

 

Clonal Hematopoiesis in Patients with WM

Adam Sperling, Dana Farber Cancer Institute, USA

 

[8:45] Panel Discussion, All Session I Speakers

 

[9:00-10:00] Session II

WM/LPL Genomics I

Bruno Paiva, Christopher Oakes [Chairs]

 

Using Mutographs to Define the Molecular Landscape and Cell of Origin of WM

Gareth Morgan, N.Y.U. Grossman School of Medicine, USA

 

Molecular Clusters and Tumor-immune Drivers of IgM Monoclonal Gammopathies

Patrizia Mondello, Mayo Clinic, USA

 

Clonal architecture and evolutionary history of WM at the single-cell level

Cristina Jiménez, Hospital Universitario de Salamanca, Spain

Chromatin Accessibility Landscape and Regulatory Networks of IgM monoclonal Gammopathies

David Moreno, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

 

 

[9:45] Panel Discussion, All Session II Speakers

 

 

[10:00-10:30] Morning Break

 

 

[10:30-11:30] Session III

WM/LPL Genomics II

Nikhil Munshi, Marzia Varettoni [Chairs]

 

Harnessing Epigenetic Signatures for Classification of WM

Christopher Oakes, Ohio State University, James Comprehensive Cancer Center, USA

 

Landscape of IgH gene repertoire and clinical relevance to LPL/WM

Mu Hao, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital, China

 

Single Cell multi-omics for minimally invasive assessment of Treatment efficacy in WM

Bruno Paiva, Clinica Universidad de Navarra, Spain

 

TP53 Alterations in the Management of Waldenstrom’s Macroglobulinemia

Steven Treon, Dana Farber Cancer Institute, USA

 

[11:15] Panel Discussion, All Session III Speakers

 

 

[11:30-12:30] Session IV

Single Cell RNA Analysis

Irene Ghobrial/Bruno Paiva [Chairs]

 

Single-Cell RNA Analysis of Tumor and Immune Cells in Asymptomatic WM

Romanos Sklavenitis-Pistofidis, Harvard Medical School, Broad Institute of MIT & Harvard , USA

 

Single-Cell RNA Analysis of MYD88 MUT and WT WM

Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece

 

Single-Cell RNA reveals Stem Cell like subsets in WM Progression

Xinxin Cao, Peking Union Medical College Hospital, China

 

Single-Cell RNA reveals Tumor Heterogeneity and Immunosuppressive Microenvironment in WM

Hao Sun, Dana Farber Cancer Institute, USA

 

[12:15] Panel Discussion, All Session IV Speakers

 

 

[12:30-13:30] LUNCH

 

 

[13:30-14:00] Session V

Keynote Lectures

 

Sub-typing WM by Multi-Omic Analysis

Keynote Moderator: Christian Buske

Keynote Speaker: Zachary Hunter, Dana Farber Cancer Institute, USA

 

BM Stromal Cells and Transcriptional Regulation: Lessons for WM

Keynote Moderator: Christian Buske

Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA

 

 

[14:00-15:00] Session VI

Molecular Diagnostics in WM

Ramón García Sanz/Roman Hajek [Chairs]

 

Clinical Implications of Genomic Profiling

Carlos Fernandez de Larrea Rodríguez, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

 

Digital Droplet (ddPCR) for Detection of MYD88 L265P Variants

Daniela Drandi, Università di Torino/Ematologia Universitaria, Italy

 

Molecular Remissions is an Independent Predictor of Progression-Free Survival in WM

Marzia Varettoni, Fondazione IRCCS Policlinico San Matteo, Italy

 

Digital Droplet (ddPCR) for Detection of CXCR4 Nonsense Variants

Nickolas Tsakmaklis, Dana Farber Cancer Institute, USA

 

[14:45] Panel Discussion, All Session VI Speakers

 

[15:00-15:30] Afternoon Break

 

[15:30-16:30] Session: VII

MYD88 and BTK Signaling Networks

Ken Anderson/Adrian Wiestner [Chairs]

 

MYD88 Signaling Cascades

Steven Treon, Dana Farber Cancer Institute, USA

 

MYD88 L265P Genocopies Activation by Phosphorylation at the TOLL/IL1 receptor (TIR) Domain

Steven Pals, University of Amsterdam, The Netherlands

 

IRAK Signaling Pathways Demonstrate Divergent Kinase and Scaffold Function

Xia Liu, Dana Farber Cancer Institute, USA

 

Aberrant Expression of Spliced WNK2 Is an Early event in MYD88-Mutated WM that Activates ERK 1/2

and supports Tumor Growth

Maria Luisa Guerrera, Dana Farber Cancer Institute, USA

 

 

[16:15] Panel Discussion, All Session VII Speakers

 

 

[17:00-18:00] Session: VIII

Plenary Session I

Gareth Morgan, Zachary Hunter [Chairs]

PLEN 1

TBD

 

PLEN 2

TBD

 

PLEN 3

TBD

 

PLEN 4

TBD

 

[17:45] Panel Discussion, All Session VIII Speakers

 

 

[19:00] Gala Dinner Reception

  • Keynote Speaker: TBD
  • Presentation of Jan Gosta Waldenstrom Awards
  • Presentation of Robert A. Kyle Awards

Friday, October 18, 2024

[8:00-9:00] Session IX

Tumor Immune Microenvironment

Stephen Ansell/ José Martínez Climent [Chairs]

 

Dysfunctions of Innate and Adaptive Immune Tumor Microenvironment in WM

Jana Jakubikova, Cancer Research Institute, Biomedical Research Center SAS, Slovakia

 

Deciphering the Immune Microenvironment in WM

Aldo Roccaro, ASST Spedali Civili di Brescia, Italy

 

Analysis of Molecular and Microenvironment Landscape and Its Role in Drug Resistance in WM

Damien Roos-Weil, Sorbonne University, Groupe hospitalier Pitié-Salpêtrière, France

 

The Characterization and Modeling of MYD88 L265P mutation and Chromosome 6q Deletion in Murine B-Cells

Ruben Carrasco, Dana Farber Cancer Institute, USA

 

[8:45] Panel Discussion, All Session IX Speakers

 

 

[9:00-10:00] Session X

Chemoimmunotherapy in WM I

Evangelos Terpos/M.J. Kersten [Chairs]       

 

Dexamethasone, rituximab, and cyclophosphamide (DRC) versus Bortezomib-DRC (B-DRC) in WM

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

Long-term Outcomes of FILO Study: Frontline Benda-Rituximab in WM

Veronique Leblond, Hôpital Pitié Salpêtrière,France

 

Multicenter Observational Study of Benda-Rituximab vs. RCD

Francesco Autore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy

 

Long-term Outcomes of 678 patients with symptomatic WM

Elham Askari, Hospital Universitario Fundación Jiménez Díaz, Spain

 

[9:45] Panel Discussion, All Session X Speakers

 

 

[10:00-10:30] Morning Break

 

 

[10:30-11:30] Session XI

Chemoimmunotherapy in WM II

Veronique Leblond/Meletios Dimopoulos [Chairs]

 

Role of Proteasome Inhibitors in WM

M.J. Kersten, University of Amsterdam, The Netherlands

 

Management of Transformed WM

Eric Durot, Hopital Robert Debre, Hematologie Clinique, France

 

Final Analysis of Innovative Study; Ibrutinib Rituximab vs. Placebo/Rituximab: Clinical and Genomic Findings

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

Comparative Outcomes of Benda-R vs. Ibrutinib in Frontline WM

Jithma Abeykoon, Mayo Clinic, USA

 

[11:15] Panel Discussion, All Session XI Speakers

 

[11:30-12:30] Session XII

BTK-Inhibitors in WM I

Stathis Kastritis/ Marek Trneny [Chairs]

 

Long Term Findings of ASPEN Study: Clinical Outcomes

Meletios Dimopoulos, University of Athens School of Medicine, Greece

 

Long Term Updates on Ibrutinib and Venetoclax in Frontline WM

Jorge Castillo, Dana Farber Cancer Institute, USA

 

ECWM-2 Prospective Study

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

BRAWM Study: Bendamustine, Rituximab and Acalabrutinib in Frontline WM

Neil Berinstein, Odette Cancer Center, Canada

 

[12:15] Panel Discussion, All Session XII Speakers

 

 

[12:30-13:30] LUNCH

 

 

 

 

 

[13:30-14:30] Session: XIII

BTK-Inhibitors in WM II

Alessandra Tedeschi/ Ranjana Advani [Chairs]

 

Pirtobrutinib in relapsed/refractory WM: Results from Bruin Study

  1. Lia Palomba, Memorial Sloan-Kettering Cancer Center, USA

 

Tirabrutinib in Symptomatic WM and Bing-Neel Syndrome (BNS)

Naohiro Sekiguchi, National Hospital Organization Disaster Medical Center ,Japan

 

Orelabrutinib in Relapsed/Refractory WM: Long-Term Follow-up

Xinxin Cao, University of Jinan, School of Biological Science & Technology, China

 

Prospective Study of Acalabrutinib and Rituximab in Symptomatic Anti-MAG mediated IgM peripheral neuropathy

Shayna Sarosiek, Dana Farber Cancer Institute, USA

 

[14:15] Panel Discussion, All Session XIII Speakers

 

 

[14:30-15:30] Session: XIV

BTK-I Intolerant and Resistant Disease

Carlos Fernández de Larrea Rodríguez, Prashant Kapoor [Chairs]

 

Dose reduction following ibrutinib intolerance in WM patients

Shayna Sarosiek, Dana Farber Cancer Institute, USA

 

Zanubrutinib for patient’s intolerant of prior BTK-I

Mazyar Shadman, Fred Hutchinson Cancer Research Center, USA

 

Bortezomib for Patients Failing BTK-I

Jahanzaib Khwaja, University College London Hospitals, UK

 

BGB-16673 BTK Degrader

John Seymour, Peter MacCallum Cancer Centre, Australia

 

[15:15] Panel Discussion, All Session XIV Speakers

 

 

[15:30-16:30] Session XV

Keynote Lectures

 

Genomic Evolution and Resistance Following BTK-Inhibitors in CLL:

Lessons for Sequencing and Managing BTK-Inhibitors

Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, USA

Keynote Speaker: Jennifer Brown, Dana Farber Cancer Institute, USA

 

Role of BTK Inhibitors as Facilitators of Cellular Immunotherapies

Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, USA

Keynote Speaker: Adrian Wiestner, NHLBI, NIH, Hematology Branch, USA

 

[16:30-17:00] Session XVI

IWWM12 Poster Highlights

Andrew Branagan, Josephine Vos [Chairs]

 

[17:00-18:30] Poster Session

 

[19:00] Faculty Dinner Reception

Saturday, October 19, 2024

[8:00-9:00] Session XVII

Special Topics Lectures

Moshe Gatt, Claudio Cerchione [Chairs]

 

Management of IgM De-myelinating neuropathy

Speaker: Shirley D’Sa, UC London Hospitals NHS, UK

 

Management of Bing Neel Syndrome

Speaker: Monique Minnema, University of Utrecht, The Netherlands

 

Diagnostic Workup and management of WM-related Amyloid

Speaker: Giampaolo Merlini, University of Pavia, Italy

 

Diagnostic Workup and Management of Monoclonal IgM-related Cold Agglutinin Disease

Speaker: Josephine Vos, University of Amsterdam, The Netherlands

 

 

[8:45] Panel Discussion, All Session XVII Speakers

 

 

[9:00-10:00] Session: XVIII

Plenary Session II

Ranjana Advani, Meletios Dimopoulos [Chairs]

PLEN 5

TBD

 

PLEN 6

TBD

 

PLEN 7

TBD

 

PLEN 8

TBD

 

[9:45] Panel Discussion, All Session XVIII Speakers

 

 

[10:00-10:30] Morning Break

 

 

[10:30-12:30] Session XIX

Great Debates in WM

Eva Kimby, Irene Ghobrial [Chairs]

 

[10:30-11:00] Great Debate I

What should be the standard Frontline Treatment for WM: Benda-R?

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. of Internal Medicine III,  Germany

 

What should be the standard Frontline Treatment for WM: CDR?

Stathis Kastritis, National and Kapodistrian University of Athens, Greece

 

What should be the standard Frontline Treatment for WM: BTK-I?

Alessandra Tedeschi, A. O. Ospedale Niguarda Ca' Granda, Italy

 

[11:00-11:30] Great Debate II

Definitive Duration Combination Therapy with BTK-I

Neil Berinstein, Odette Cancer Center, Canada

 

Single-Agent Indefinite Duration BTK-I

Prashant Kapoor, Mayo Clinic, USA

 

[11:30-12:00] Great Debate III

Patients with Acquired Covalent BTK-Inhibitor Resistance: Pirtobrutinib?

  1. Lia Palomba, Memorial Sloan Kettering Cancer Center, USA

 

Patients with Acquired Covalent BTK-Inhibitor Resistance: Venetoclax?

Jorge Castillo, Dana Farber Cancer Institute, USA

 

[12:00-12:30] Great Debate IV

Should TP53 Alterations be Factored into Treatment Decision making -yes?

Ramon Garcia Sanz, University Hospital Gregorio Marañón, Spain

 

Should TP53 Alterations be Factored into Treatment Decision making -no?

Shirley D’Sa, University College London Hospitals NHS Trust, UK

 

 

[12:30-13:30] LUNCH

 

[13:30-14:30] Session XX

Novel Drug Development for WM

Ramon Garcia Sanz, Lugui Qiu [Chairs]

 

Development of Highly potent and selective biovailable Protacs (proteolysis-targeting chimeras) targeting HCK

John Hatcher, Dana Farber Cancer Institute, USA

 

Development of IRAK1/IRAK4 Bifunctional Protacs (proteolysis-targeting chimeras)  for MYD88 mutated WM

Sara Buhrlage, Dana Farber Cancer Institute, USA

 

Pacritinib is a Highly Potent Inhibitor of HCK and IRAK and Triggers High Levels of Apoptosis in WM

Shirong Liu, Dana Farber Cancer Institute, USA

 

Pre-clinical Models for Prediction of Immunotherapy Outcomes and Immune Evasion

Jose Martínez Climent, University of Navarra, Spain

 

[14:15] Panel Discussion, All Session XX Speakers

 

[14:30-15:30] Session XXI

Clinical Trials in Progress for WM I

Jeffrey Matous, Shayna Sarosiek [Chairs]

 

Carfilzomib With and Without Ibrutinib in Frontline and Relapsed/Refractory WM (CZAR-1)

Meletios Dimopoulos, University of Athens School of Medicine, Greece

 

Rainbow Trial: Ibrutinib Rituximab vs. DRC in Newly diagnosed WM

Rebecca Auer, Barts Health NHS Trust, UK

 

Zanubrutinib plus Benda-R in Newly diagnosed WM

Shuhua Yi, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), China

 

Pirtobrutinib and Venetoclax in relapsed or refractory WM

Jorge Castillo, Dana Farber Cancer Institute, USA

 

[15:15] Panel Discussion, All Session XXI Speakers

 

 

[15:30-16:00] Afternoon Break

 

[16:00-17:00] Session XXII

Clinical Trials in Progress for WM II

Evangelos Terpos/ Prashant Kapoor [Chairs]

 

Loncastuxumab in Relapsed/Refractory WM

Shayna Sarosiek, Dana Farber Cancer Institute, USA

 

Sonrotoclax for Relapsed/Refractory WM

Jeffrey Matous, Colorado Blood Cancer Institute, USA

 

Multi-center Trial of Ipofosine in Relapsed/Refractory WM

Andrei Shustov, Cellectar Biosciences, USA

 

CD20-Directed CAR-T Cell

Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA

 

[16:45] Panel Discussion, All Session XXII Speakers

 

 

 

[17:00-18:00] Session XXIII

Clinical Trials in Progress for WM III

Roger Owen, Pierre Morel [Chairs] 

 

WM-NET Clinical Trial Priorities

Jorge Castillo, Dana Farber Cancer Institute, USA

 

ECWM Clinical Trial Priorities

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

 

[19:30] Dinner Reception and Closing Ceremonies

  • Keynote Speaker:
  • Presentation of Peter S. Bing Humanitarian Awards
  • Presentation of Junior Investigator Awards
  • Announcement and Welcome to IWWM-13
Coming soon

The Bing Center

ing Center for Waldenstrom's Macroglobulinemia
Dana Farber Cancer Institute
Harvard Medical School

Contact

Christopher Patterson
Secretariat

Address

450 Brookline Avenue

Mayer 630

Boston, MA 02215

p +1 857 215 2763

f +1 617 632 4862